The CORALreef Lipids trial in patients with elevated cholesterol (hypercholesterolaemia) at risk of atherosclerotic ...

In the 24-week trial, MSD's drug showed meaningful reductions in LDL cholesterol, when compared to placebo. In June, the ...

Antibody-drug conjugates (ADCs) and other next-generation drug modalities are unlocking new treatment possibilities. However, ...

MSD is slashing $3bn (€2.59bn) from its annual spending as it braces for off-brand competition to its Irish-manufactured cancer drug Keytruda, the best-selling medicine in the world. The drugmaker ...